Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Tory

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Cancer Research|February 15, 1991
Molecular analysis of genetic changes in the origin and development of renal cell carcinomaP Anglard, K Tory, H Brauch, et al.
Science (New York, N.Y.)|May 28, 1993
Identification of the von Hippel-Lindau disease tumor suppressor geneF Latif, K Tory, J Gnarra, et al.
Clinical Nephrology|June 9, 2004
Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trialK Tory, E Horváth, Z Süveges, et al.
Journal of the National Cancer Institute|July 19, 1989
Specific genetic change in tumors associated with von Hippel-Lindau diseaseK Tory, H Brauch, M Linehan, et al.
Nature Genetics|May 1, 1994
Mutations of the VHL tumour suppressor gene in renal carcinomaJ R Gnarra, K Tory, Y Weng, et al.
Human Genetics|December 1, 1993
von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresisM Yao, F Latif, M L Orcutt, et al.
Genes, Chromosomes & Cancer|January 1, 1990
Molecular mapping of deletion sites in the short arm of chromosome 3 in human lung cancerH Brauch, K Tory, F Kotler, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 14, 2009
Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trialB Literáti-Nagy, E Kulcsár, Zs Literáti-Nagy, et al.
Toxicology and Applied Pharmacology|July 2, 2003
BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in ratsG Bárdos, K Móricz, L Jaszlits, et al.
Brain Research Bulletin|September 21, 2010
Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disordersB Literáti-Nagy, E Péterfai, E Kulcsár, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Cancer Research|February 15, 1991
Molecular analysis of genetic changes in the origin and development of renal cell carcinomaP Anglard, K Tory, H Brauch, et al.
Science (New York, N.Y.)|May 28, 1993
Identification of the von Hippel-Lindau disease tumor suppressor geneF Latif, K Tory, J Gnarra, et al.
Clinical Nephrology|June 9, 2004
Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trialK Tory, E Horváth, Z Süveges, et al.
Journal of the National Cancer Institute|July 19, 1989
Specific genetic change in tumors associated with von Hippel-Lindau diseaseK Tory, H Brauch, M Linehan, et al.
Nature Genetics|May 1, 1994
Mutations of the VHL tumour suppressor gene in renal carcinomaJ R Gnarra, K Tory, Y Weng, et al.
Human Genetics|December 1, 1993
von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresisM Yao, F Latif, M L Orcutt, et al.
Genes, Chromosomes & Cancer|January 1, 1990
Molecular mapping of deletion sites in the short arm of chromosome 3 in human lung cancerH Brauch, K Tory, F Kotler, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 14, 2009
Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trialB Literáti-Nagy, E Kulcsár, Zs Literáti-Nagy, et al.
Toxicology and Applied Pharmacology|July 2, 2003
BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in ratsG Bárdos, K Móricz, L Jaszlits, et al.
Brain Research Bulletin|September 21, 2010
Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disordersB Literáti-Nagy, E Péterfai, E Kulcsár, et al.
Pageof 6